Respiratory Drug Delivery IX

Respiratory Drug Delivery IX (RDD®) was held at the Desert Springs Marriott Resort and Spa in Palm Desert, California, from April 25 to 29, 2004. For the ninth time in sixteen years, this series of international symposia organized by Virginia Commonwealth University School of Pharmacy successfully brought together participants from academia, government, and the pharmaceutical industry. More than 640 conference attendees including 145 scientific poster presenters and 75 suppliers gathered in California to exchange the latest developments in the area of drug delivery to the lungs, making this year’s conference the largest in its history.

The scientific program ran for four days, and individual sessions targeted:

• Pathophysiology of Chronic Airways Disease: Therapeutic Concepts for the Future
• New Therapeutic Insights
• Comprehending and Controlling Drug Disposition in the Lung
• Steroid - Long Acting Beta Agonist Interactions
• Next Generation MDIs: Debating the Design Options
• New Concepts in Regulatory Science
• Selection and Validation of Cascade Impactor Test Methods (which will be available soon as an online seminar)
• In Vivo- In Vitro Correlations - New Developments
• Nasal Targeting
• Soft Mist Inhaler Developments
• New Powder Science for Inhalers

The pre-prints of all podium sessions and posters were published by Davis Healthcare International Publishing and are also available electronically on RDD Online. A complete list of all of the Scientific Poster presentations can be found in RDD IX Proceedings. They cover a broad selection of topics related to pulmonary and nasal drug delivery, and each one has been peer reviewed. In addition, our Table Exhibition includes over 75 companies encompassing all aspects of inhaled drug delivery technology.

A special thanks to the sponsors of RDD IX 2004

3M Drug Delivery Systems, Abbott Laboratories, Aradigm Corporation, AstraZeneca, Aventis, Bespak, Boehringer Ingelheim, Cardinal Health, Chiesi Farmaceutici, Chiron Corporation, Chrysalis Technologies, Copley Scientific, Corus Pharma, CTBR Bio-Research, Forest Laboratories, GlaxoSmithKline, Hoffman-La-Roche, Ineos Fluor, Kos Pharmaceuticals, Merck Research Laboratories, MSP Corporation, Nektar Therapeutics, NextBreath, Novartis, Pamasol Willi Mader AG/DH Industries, PPD Development, Profile Therapeutics, Quintiles, Solvay Fluorides, Trudell Medical International, Valois, Wyeth